Neurocrine Biosciences account plan
Developing treatments for disorders
At a glance
Neurocrine Biosciences is a San Diego neuroscience biopharma company with $2,860.5 million FY2025 revenue and about 2,000 employees.
Neurocrine Biosciences is a San Diego neuroscience-focused biopharmaceutical company that discovers, develops and sells treatments for neurological, psychiatric, endocrine and immunological disorders, primarily in the U.S. Its marketed medicines are INGREZZA (tardive dyskinesia and Huntington's chorea), CRENESSITY (classic congenital adrenal hyperplasia) and, since the May 2026 Soleno Therapeutics acquisition, VYKAT XR for hyperphagia in Prader-Willi syndrome. FY2025 total revenues were $2,860.5 million (2024: $2,355.3 million), with net income of $478.6 million and about 2,000 full-time employees at year-end. It relies on third-party manufacturers and reports a single segment.
Business units
INGREZZA (valbenazine)
about 88% of FY2025 total revenues ($2,513.7 million, computed)VMAT2 inhibitor for tardive dyskinesia and Huntington's chorea, sold in the U.S. through a limited specialty network and in Asia by Tanabe Pharma. Q3 2026 sales were $801.5 million (Q3 2025: $686.6 million), and 2026 guidance was raised to $2,900-2,925 million.
CRENESSITY (crinecerfont)
about 11% of FY2025 total revenues ($301.2 million, computed)First new treatment for classic CAH in over 70 years, launched in December 2024 and sold through a single specialty pharmacy. Q3 2026 sales were $210.8 million, up from $98.1 million, with more than 15% of U.S. classic CAH patients prescribed.
VYKAT XR (diazoxide choline)
The only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, added with Soleno Therapeutics in May 2026. It brought $106.7 million in Q3 2026, its first full quarter.
Other revenues (ALKINDI, EFMODY, royalties)
about 2% of FY2025 total revenues ($45.6 million, computed)Other net product sales of $19.0 million in 2025, plus collaboration revenues of $26.6 million, mainly royalties from AbbVie on elagolix and Tanabe Pharma on valbenazine.
Research and development pipeline
R&D expense was $1,015.7 million in 2025 (35.5% of revenues), covering Phase 3 osavampator (major depressive disorder) and direclidine (schizophrenia), muscarinic programs, obesity peptides, immunology and gene therapy with Voyager.
Strategic priorities
- Grow the three commercial medicines
- Maximize INGREZZA, CRENESSITY and VYKAT XR; the sales force of approximately 600 was expanded in Q1 2026, and full-year 2026 INGREZZA guidance was raised to $2,900-2,925 million.
- Phase 3 readouts in 2027
- Initial Phase 3 topline data for osavampator in major depressive disorder and direclidine in schizophrenia are expected in 2027, with a second direclidine Phase 3 in 2028.
- Steady flow of new medicines
- The company aims to launch about one new medicine every two years and to advance at least four new programs into Phase 1 and two into Phase 2 each year; 2026 brought 6 Phase I and 5 new Phase II starts.
- Obesity and immunology expansion
- NBIP-2118 (CRF2 agonist) and NBIP-1968 (GLP-1/GIP/glucagon triple agonist) are in Phase 1 to inform a co-formulated combination, and NBIM-'1008 started Phase 1 for rheumatoid arthritis.
- Move into biologics and gene therapy
- R&D is being transformed to include peptides, proteins, antibodies, conjugates and gene therapies, with substantial investment in personnel and facilities.
Latest results
In Q3 2026 (three months to September 30, 2026) total revenues were $1,122.7 million, up from $794.9 million, and net product sales exceeded $1 billion for the first time. INGREZZA grew 17% to $801 million (including a $20 million order-timing benefit expected to reverse in Q4), CRENESSITY rose 115% to $211 million and VYKAT XR added $107 million. GAAP net income was $206.5 million ($1.96 per share) against $209.5 million, weighed by a $52.3 million unrealized loss on equity investments; non-GAAP net income was $347 million. Full-year 2026 INGREZZA guidance was raised to $2,900-2,925 million and GAAP SG&A guidance lowered to $1,540-1,560 million, with GAAP R&D unchanged at $1,275-1,325 million.
Investments and deals
- Soleno Therapeutics acquisition
- All-cash acquisition closed May 18, 2026, with a total equity value of approximately $2.9 billion, adding VYKAT XR; product rights valued at $2.2 billion are amortized over 16 years.
- Revolving credit facility
- A five-year $1.0 billion senior secured revolving credit facility signed in May 2026; $600.0 million was borrowed in May and repaid in June.
- In-licensing partnerships
- Deals with Nxera (direclidine), Takeda (osavampator), Xenon and Voyager; potential future milestone payments under collaborations rose to up to $16.5 billion.
- Share repurchases
- 1.1 million shares were repurchased for $158.1 million in the first nine months of 2026, with $174.2 million remaining under the 2025 program.
- Divestment of Neurocrine Group Limited
- Sold to Immedica Pharma AB on January 21, 2026 for $63.2 million in cash.
Challenges and risks
- Dependence on INGREZZA
- INGREZZA was about 88% of FY2025 revenues and faces Teva's AUSTEDO, whose lower Medicare negotiated price "may increase competitive pressures on INGREZZA".
- Drug pricing pressure
- INGREZZA's Medicare negotiated price applies from 2029, and the CFO expects mid- to high single-digit net pricing headwinds in 2027.
- Legal and regulatory scrutiny
- A DOJ civil investigative demand on INGREZZA sales and marketing was received in August 2025, alongside patent challenges such as Zydus's ANDA on INGREZZA SPRINKLE.
- Clinical risk
- In 2025 Phase 3 studies of valbenazine in schizophrenia and in dyskinesia due to cerebral palsy missed their primary endpoints, and VYKAT XR growth may be delayed after safety reports in the media.
- Reliance on third-party manufacturing
- Neurocrine has no manufacturing of its own and depends on a limited number of third-party suppliers, while expanding into biologics and device-based therapies.
What leadership says
“another important milestone in Neurocrine's evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines”
“Never in Neurocrine's 35-year history, we have achieved this level of R&D productivity in a single year.”
“Just a few years ago, we were largely viewed as a single product company.”
“driving commercial growth, advancing high-value pipeline programs and pursuing disciplined business development”
Where a supplier can help
- Contract manufacturing and supply
- With no in-house manufacturing and a move into biologics (challenge: reliance on third-party manufacturing; priority: move into biologics), CDMOs, peptide and biologics manufacturers and supply chain partners fit.
- Clinical trial services
- Phase 3 programs for osavampator and direclidine plus many new Phase 1 and Phase 2 starts (priority: Phase 3 readouts in 2027) call for CRO, site, patient recruitment and data services.
- Commercial and field sales tools
- The expanded sales force and possible primary-care launch (priority: grow the three commercial medicines) need CRM, field analytics, HCP engagement and patient services support.
- Compliance and market access
- The DOJ inquiry and Medicare pricing pressure (challenges: legal and regulatory scrutiny, drug pricing pressure) make compliance monitoring, pricing analytics and payer-contracting tools relevant.
- Integration support
- Integrating Soleno and VYKAT XR (investment: Soleno Therapeutics acquisition) opens room for integration, rare-disease patient support and pharmacovigilance services.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Neurocrine Biosciences?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 10-K for fiscal year 2025
- Neurocrine Biosciences is a San Diego neuroscience-focused biopharmaceutical company with FDA-approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids (with AbbVie); about 2,000 full-time employees as of December 31, 2025.
- FY2025 total revenues were $2,860.5 million (2024: $2,355.3 million); net income $478.6 million, diluted EPS $4.67; total net product sales rose $503.3 million, or 21.6%, to $2.83 billion.
- INGREZZA (valbenazine) is the engine: net product sales of $2.51 billion in 2025 ($2.31 billion in 2024), on record total prescriptions but a lower net price due to new market access investments; formulary coverage now includes approximately 70% of TD and Huntington's disease Medicare beneficiaries.
- CRENESSITY (crinecerfont), launched December 2024 as the first new CAH treatment in over 70 years, made $301.2 million in its first full year.
- Neurocrine reports a single segment and relies on third-party manufacturers; it sells INGREZZA through a limited specialty network and CRENESSITY through a single specialty pharmacy, with a sales force of approximately 600 being expanded by end of Q1 2026.
- R&D spend reached $1,015.7 million (35.5% of revenues); Phase 3 programs for osavampator (MDD) and direclidine (schizophrenia) have initial topline data expected in 2027; the company aims to launch about one new medicine every two years and to advance at least four new programs into Phase 1 and two into Phase 2 each year.
- Expansion into biologics (peptides, proteins, antibodies, conjugates, gene therapies), obesity (CRF-2 agonist NBIP-2118, Phase 1 planned H1 2026) and immunology; potential future milestone payments under collaborations of up to $14.87 billion.
- Key risks: dependence on INGREZZA, competition from Teva's AUSTEDO (whose lower Medicare negotiated price may add pricing pressure), IRA price negotiation (INGREZZA exempt until 2027 selection for 2029 pricing), a DOJ civil investigative demand on INGREZZA sales and marketing (August 2025), and Phase 3 failures (valbenazine in schizophrenia and dyskinesia due to cerebral palsy).
- Cash, cash equivalents and marketable securities were $2,543.4 million at year-end 2025; $332.3 million remained under the $500.0 million 2025 share repurchase program.
- Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 (three months to September 30, 2026) total revenues were $1,122.7 million vs $794.9 million a year earlier; net income $206.5 million (Q3 2025: $209.5 million), diluted EPS $1.96.
- Nine-month total net product sales grew $848.7 million, or 41.7%, to $2.9 billion.
- Q3 net product sales: INGREZZA $801.5 million (Q3 2025: $686.6 million), CRENESSITY $210.8 million ($98.1 million), and VYKAT XR $106.7 million in its first full quarter.
- Neurocrine completed the all-cash acquisition of Soleno Therapeutics on May 18, 2026 (total equity value approximately $2.9 billion), adding VYKAT XR, the only FDA-approved treatment for hyperphagia in Prader-Willi syndrome; $2.2 billion of intangibles are amortized over 16 years.
- Neurocrine Group Limited was sold to Immedica Pharma AB for $63.2 million in January 2026.
- Cash and marketable securities fell to $789.7 million (from $2,543.4 million at December 31, 2025) after the Soleno deal; a new $1.0 billion revolving credit facility was undrawn at September 30, 2026.
- R&D was $351.8 million in Q3 (Phase 3 direclidine and osavampator, obesity and immunology); SG&A $366.3 million, including the Q1 2026 sales force expansion.
- Management changes: Eiry W. Roberts returned as CMO, Samir Siddhanti became Chief Business Officer and Andrew Ratz Chief Technical Operations Officer.
- New programs in 2026: Phase 2 starts for NBI-1117567 (Alzheimer's cognition), NBI-1117570 (schizophrenia) and crinecerfont in children under 4; Phase 1 starts for NBIP-'2118 and NBIP-'1968 (obesity) and NBIM-'1008 (rheumatoid arthritis).
- Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
- Q3 2026 total revenues were $1,123 million, up 41% year over year from $795 million; net product sales topped $1 billion for the first time.
- INGREZZA $801 million (+17%), with record TRx and NRx; CRENESSITY $211 million (+115%), with approximately 80% reimbursement for dispensed prescriptions; VYKAT XR $107 million.
- Full-year 2026 INGREZZA guidance raised to $2.9-2.925 billion (from $2.825-2.875 billion).
- 2026 GAAP SG&A guidance lowered to $1,540-1,560 million; GAAP R&D guidance unchanged at $1,275-1,325 million; IPR&D raised to $34 million.
- GAAP net income $207 million ($1.96 per share); non-GAAP net income $347 million ($3.29 per share), vs $222 million ($2.17) a year earlier.
- Cash, cash equivalents and marketable securities about $790 million at September 30, 2026.
- Obesity strategy: NBIP-'1968 (GLP-1/GIP/glucagon triple agonist) and NBIP-'2118 (CRF2 agonist) in Phase 1, to inform a co-formulated combination.
- CEO Kyle Gano expects 2027 growth across INGREZZA, CRENESSITY and VYKAT XR plus Phase 3 readouts for osavampator (MDD) and direclidine (schizophrenia); R&D Day on December 15, 2026.
- Neurocrine Biosciences Q3 2026 earnings call transcript
- CEO Kyle Gano: record Q3 2026 net product sales of more than $1.1 billion and record profitability from "3 first-in-class medicines"; 2027 will bring Phase III readouts for osavampator (MDD) and direclidine (schizophrenia).
- CFO Matt Abernethy: INGREZZA $801 million (+17%) included a $20 million order-timing benefit that reverses in Q4; 2026 prescription growth is expected in the high-teens; for 2027, double-digit volume growth should more than offset mid- to high single-digit net pricing headwinds.
- INGREZZA payer contracting for 2027 is nearly done, with access "at least as good as this year" (about 70% of Medicare lives covered in 2026); only about 10% of the TD population is on a VMAT2 inhibitor.
- CRENESSITY: $211 million, over 15% of the diagnosed classic CAH population prescribed; roughly half of patients are adults; Gano says it set "a very high bar" against competition.
- VYKAT XR: $107 million on net patient adds; after "recent external events" around safety, growth may be "a little bit more delayed"; a 2027 study in PWS patients with complex health issues is planned; average dose around 250 mg, about $550,000 per year.
- Capital: about $800 million cash, $400 million operating cash flow in the quarter, about $100 million of buybacks; BD focused on neurology, psychiatry, endocrinology and soon immunology, with no pressure to do a deal.
- Obesity: CRF2 agonist NBIP-2118 (once-weekly peptide, muscle-preserving) and the GGG triple agonist NBIP-1968 pursued as a mix-and-match combination strategy.
- 2026 R&D output: 6 Phase I and 5 new Phase II starts, which Gano calls unprecedented in Neurocrine's 35-year history.
- Neurocrine Biosciences Q2 2026 earnings call transcript
- CEO Kyle Gano: Q2 2026 product sales exceeded $950 million; "Just a few years ago, we were largely viewed as a single product company"; strategy is to execute commercially, advance the innovation engine and deploy capital with discipline.
- INGREZZA $716 million (+15%), record new patient starts; 2026 guidance raised to $2.825-2.875 billion, about 13% growth at the midpoint; about 70% of Medicare lives covered in 2026.
- CRENESSITY $184 million; about 15% of the diagnosed population prescribed; prescriber base nearly tripled in a year; over 90% of patients pay $10 or less per month.
- VYKAT XR: $94 million pro forma, $54 million booked from the May 18 close; Benevich sees it as a potential "third blockbuster"; discontinuations should settle at 25-30%, with sequential growth expected exiting 2026.
- Soleno bought for about $2.9 billion with cash on hand; about $500 million cash and no debt at quarter end; about $150 million of acquisition costs, $130 million in Q2; non-GAAP operating income over 30%.
- IRA: INGREZZA's Medicare negotiated price applies from 2029; Abernethy expects some EPS variability, plus a sales force build in primary care if osavampator succeeds.
- Pipeline: osavampator and first direclidine Phase 3 readouts in H2 2027, second direclidine Phase 3 in 2028; four muscarinic shots on goal; CRF2 agonist obesity readout next year.
Questions about Neurocrine Biosciences
What does Neurocrine Biosciences do?
It is a San Diego neuroscience-focused biopharmaceutical company selling INGREZZA, CRENESSITY and VYKAT XR, and developing treatments in psychiatry, neurology, endocrinology, obesity and immunology.
What is Neurocrine Biosciences' revenue?
FY2025 total revenues were $2,860.5 million (2024: $2,355.3 million). In Q3 2026 total revenues reached $1,122.7 million.
How many employees does Neurocrine Biosciences have?
About 2,000 full-time employees as of December 31, 2025, primarily in the U.S.
Who leads Neurocrine Biosciences?
Kyle W. Gano is Chief Executive Officer, Matthew C. Abernethy is Chief Financial Officer and William H. Rastetter chairs the Board.
What is Neurocrine Biosciences' strategy?
Grow its three marketed medicines, deliver Phase 3 readouts for osavampator and direclidine in 2027, launch about one new medicine every two years and diversify into obesity, immunology and biologics.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)